MAPT and Alzheimer disease: As a late accelerating biomarker, tau continues to accumulate over the course of a typical early symptomatic AD trial (3) (Figure 1B); depending on the therapeutic agent and the specific brain region, the tau PET signal can be slowed, stopped, or even reduced below baseline levels (14, 53).